TheL-dopa story: Translational neuroscience ante verbum
Author:
- Hans-Peter LudinHLHans-Peter Ludin
Open Access
- 1 January 2018
- journal article
- research article
- Published by MDPI AG in Clinical and Translational Neuroscience
- Vol. 2 (1)
Abstract
Since almost 50 years L-Dopa is the gold standard for the treatment of patients with Parkinson’s disease (PD). For the first time, a specific chemical abnormality was found in a specific brain disorder. It has been shown that the striatal dopamine (DA) content is greatly reduced in PD patients. The substitution of DA by its precursor L-dopa greatly enhanced the quality of life of PD patients.Keywords
This publication has 24 references indexed in Scilit:
- TREATMENT OF PARKINSON'S SYNDROME WITH L-DOPA A DOUBLE BLIND STUDYActa Neurologica Scandinavica, 2009
- A Double Blind Study of 1-Dopa Treatment in Parkinson's Disease1European Neurology, 1968
- Weitere experimentelle Untersuchungen ber den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Chorea-Syndrom)European Archives of Psychiatry and Clinical Neuroscience, 1967
- Was leistet L-Dopa bei der Behandlung der Parkinson-Akinese?*DMW - Deutsche Medizinische Wochenschrift, 1967
- Action of d -Tubocurarine Chloride on Net Flux of Water across Isolated Frog SkinScience, 1961
- Distribution of catechol compounds in human brainBiochimica et Biophysica Acta, 1959
- Catechol Compounds in Rat Tissues and in Brains of Different AnimalsNature, 1957
- Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der DopadecarboxylaseNaunyn-Schmiedeberg's Archives of Pharmacology, 1942
- Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba.Hoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1913
- LXV.—Synthesis of dl-3 : 4-dihydroxyphenylalanineJournal of the Chemical Society, Transactions, 1911